Haisco Pharmaceutical Group Co. Ltd. has identified crystalline forms of poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising a cereblon (CRBN) binding moiety acting as protein degradation inducers reported to be useful for the treatment of anemia, cancer, diabetes, infections, transplant rejection, inflammation, autoimmune and sarcoidosis, among others.
Deciphera Pharmaceuticals LLC has disclosed serine/threonine-protein kinase ULK1 and serine/threonine-protein kinase ULK2 inhibitors reported to be useful for the treatment of cancer.
Moma Therapeutics Inc. has released data regarding their Werner syndrome helicase (WRN) inhibitor MOMA-341 for the potential treatment of cancer. MOMA-341 is a potent and selective WRN inhibitor, the action of which is through covalent ligation.
Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations.
The FDA has granted orphan drug designation to Vanda Pharmaceuticals Inc.’s VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV).
Replicate Bioscience Inc. and Novo Nordisk A/S have entered into a multiyear research collaboration that will leverage Replicate’s novel self-replicating RNA (srRNA) platform to develop new therapeutic candidates to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal, off-the-shelf immunotherapy platform that is converted into a patient-specific precision medicine in real time using a tumor biopsy.
Palobiofarma SL has announced the successful completion of an industrial research project investigating dual antagonist compounds targeting adenosine A2A and histamine H3 receptors for the treatment of Parkinson’s disease.
The signaling of ephrin B (EphB) has been shown to be involved in the progression of metabolic disorders, among others. In this context, researchers from Texas Tech University Health Sciences Center have developed a pan-EphB inhibitor – STA-013 – for the treatment of metabolic syndrome.
RSS
